-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com
Equities researchers at StockNews.com began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a "sell" rating on the stock.
BiondVax Pharmaceuticals Stock Performance
Shares of BVXV opened at $2.77 on Tuesday. The company's fifty day moving average is $6.01 and its 200-day moving average is $8.55. BiondVax Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $22.90. The firm has a market cap of $3.97 million, a price-to-earnings ratio of -0.69 and a beta of 2.65. The company has a quick ratio of 5.76, a current ratio of 5.76 and a debt-to-equity ratio of 5.92.
Get BiondVax Pharmaceuticals alerts:BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its quarterly earnings results on Wednesday, November 30th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Equities analysts expect that BiondVax Pharmaceuticals will post -0.3 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its position in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 163,423 shares of the company's stock after buying an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.About BiondVax Pharmaceuticals
(Get Rating)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
Recommended Stories
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a "sell" rating on the stock.
股票研究人員在股票新聞網開始報導 生物醫藥 (納斯達克:BVXV — 獲得評分) 在星期二向客戶和投資者發出的研究報告中。經紀公司對股票設定了「賣出」評級。
BiondVax Pharmaceuticals Stock Performance
生物醫藥股票性能
Shares of BVXV opened at $2.77 on Tuesday. The company's fifty day moving average is $6.01 and its 200-day moving average is $8.55. BiondVax Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $22.90. The firm has a market cap of $3.97 million, a price-to-earnings ratio of -0.69 and a beta of 2.65. The company has a quick ratio of 5.76, a current ratio of 5.76 and a debt-to-equity ratio of 5.92.
BVXV 的股票在星期二開盤 2.77 美元。該公司的五十天移動平均線為 6.01 美元，其 200 天移動平均線為 8.55 美元。生物醫藥有一個 12 個月低點 2.37 美元和 12 個月的高點 22.90 美元。該公司的市值為 397 萬美元，價格與收益比為 -0.69，測試版為 2.65。該公司的快速比率為 5.76，流動比率為 5.76，債務與權益比率為 5.92。
BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its quarterly earnings results on Wednesday, November 30th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Equities analysts expect that BiondVax Pharmaceuticals will post -0.3 EPS for the current fiscal year.
BiondVAX 製藥公司 (NASDAQ: BVXV — 獲取評級) 最後公佈其季度收益業績週三, 11 月 30 日.該公司報告了本季每股收益 0.06 美元，超過 0.16 美元的共識估計（0.10 美元）。股票分析師預計，BionDVAX 製藥將在當前財政年度實現 -0.3 每股收益。
Institutional Inflows and Outflows
機構流入和流出
About BiondVax Pharmaceuticals
關於生物製藥
(Get Rating)
(取得評分)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
BionDVAX 製藥有限公司是一家發展階段的生物製藥公司，致力於開發，製造和商業化以色列傳染病和其他疾病的預防和治療產品。該公司與馬克斯·普朗克學會和戈廷根大學醫學中心簽訂了許可和合作協議，以開發和商業化 COVID-19 奈米尺寸抗體（NanoAB）；以及用於其他各種疾病適應症的奈米 ABS 的開發和商業化。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
- 獲取有關 BioNDVAX 製藥公司（BVXV）的研究報告的免費副本
- 諾斯羅普·格魯曼拋售是一個機會嗎？
- 新的首席執行官在裝甲股票下最糟糕的背後是什麼？
- 分析師喜歡適合斯凱奇美國
- 微軟對聊天 GBT 的投資對 MSFT 股票意味著什麼？
- 我們可以相信標普 500 的反彈
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 BioNDVAX 藥品的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 BionDVax 製藥及相關公司的最新新聞和分析師評級的簡明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧